ClinicaliQ Trial Snapshot
- A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease — Recruiting • Phase II • NCT06830629.
- What is being tested: MZE829, an investigational therapeutic agent, is being evaluated for its safety, tolerability, and ability to reduce albuminuria (protein in urine) in adults with APOL1 kidney disease, a genetic form of chronic kidney disease.
- Patient eligibility overview: The study enrolls adult patients with confirmed APOL1 kidney disease; specific eligibility criteria typically include baseline albuminuria levels and preserved renal function thresholds, though detailed inclusion/exclusion criteria would be specified in the full protocol.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Eligibility Snapshot
- Key Inclusion Criteria: * APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2 * Chronic kidney disease with persistent albuminuria Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.